India Pharma Outlook Team | Friday, 26 December 2025
Bristol Myers Squibb (BMS) is positioning India as a key growth engine as the US-based biopharma major enters one of its most active pipeline phases while accelerating AI-led pharmaceutical commercialization.
BMS, which recorded over $48 billion in global sales last year, expects multiple global data readouts over the next 12–18 months across oncology, haematology, cardiovascular, and immunology therapies. The company is simultaneously scaling its India presence with new launches such as mavacamten (Camzyos) for hypertrophic cardiomyopathy and an expanding oncology portfolio.
Its broader pipeline includes iberdomide and marizomib for multiple myeloma, milvexian for stroke prevention and atrial fibrillation, GPRC5D cell therapy, and melpront for pulmonary fibrosis.
Also Read: How Pharma Contract Manufacturing Can Win Big in Weight-Loss Drugs
“This is a really exciting time for the company,” said Adam Lenkowsky, Executive Vice President and Chief Commercialization Officer at BMS. “In India today, we’ve been growing rapidly with our in-line products, largely in the oncology space. India is an important market where we’ve seen strong growth, great performance, and we’re looking to bring more and more products here to help more patients.”
Central to this strategy is over $100 million in AI-led commercialisation investments, anchored by a newly launched Gen AI hub in Mumbai in partnership with Accenture. The hub aims to compress drug commercialisation timelines and reduce prescriber updates on new clinical trial data from months to weeks.
“We are not leveraging India as a backend office or a GCC,” said Anvita Karara, Head of AI Commercial Transformation at BMS. “The Mumbai team is leading AI. That is true innovation.”
India is now one of BMS’s largest employee bases, with over 3,000 employees, and the AI hub is expected to serve global markets while supporting the company’s pipeline-driven growth beyond 2030.
.jpg)
.jpg)
